Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-836 in Sepsis and ALI/ARDS
NCT00879606Phase 2Completed
- Sponsor
- Altor BioScience Corporation
- Start
- Apr 2009
- Primary completion
- Oct 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ALT-836 in sepsis, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), sponsored by Altor BioScience Corporation. Started Apr 2009; status: completed.
02
Drugs
ALT-836
03
Conditions
sepsisacute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT00879606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00879606.